ArticleBMC medical research methodology2025
Restricted mean survival time approach versus time-varying coefficient Cox model for quantifying treatment effect when hazards are non-proportional.
Article in BMC medical research methodology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough the Cox time-varying coefficient (TVC) model has been developed to address non-proportional hazard (PH), its use remains underexplored. Instead, the restricted mean survival time (RMST) has been widely used in non-PH settings to quantify treatment effects using life expectancy ratio (LER) and life expectancy difference (LED).
methodsThis study explores a novel extension of the Cox TVC model under non-PH to generate LER and LED to enable a direct comparison with RMST based on flexible parametric survival model (FPM). An intensive simulation study was conducted to compare the performance of FPM to the Cox TVC model under PH and non-PH assumptions. The survival time t was assumed to follow the Piecewise Exponential distribution with various censoring patterns generated from the Uniform distribution. Both methods were evaluated via a randomised clinical trial of nasopharyngeal cancer exhibiting increasing treatment benefit.
resultsIntensive simulations showed Cox TVC outperformed FPM under non-PH in terms of bias and coverage, with generally higher power observed in scenarios of crossing or diverging curves under low censoring. In real-world data, the FPM produced slightly larger LER and LED estimates than Cox TVC. Cox TVC has the advantage of assessing treatment effect at different milestones and detecting earlier difference when estimating using hazard ratio (HR).
conclusionOverall, Cox TVC is a viable option for summarising treatment effect using LER and LED under non-PH conditions. It would be beneficial to complement the reporting by providing estimates of HR at specific milestone to detect early differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.